JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to the provision of Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copies of Newspaper advertisement published on February 03, 2024 in Business Standard (English) and Business Standard (Hindi) for the quarter and nine months ended December 31, 2023. JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Intimation Under Regulation 30(5) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 (SEBI LODR)
We wish to inform you that consequent to the appointment of Mr. Ashish Lakhotia, Chief Financial Officer of the Company, the Board of Directors have approved the Change in KMPs for authorised for the purpose of the determining the event or information for making the disclosure under SEBI LODR. JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Announcement under Regulation 30 (LODR)-Change in Management
Please find enclosed the intimation on change in Key Managerial Personnel. JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press release for the quarter and nine months ended December 31, 2023. JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Outcome Of Board Meeting Held On February 02, 2024 Along With Unaudited Financial Results For The Quarter And Nine Months Ended December 31, 2023
Please find enclosed Unaudited Financial Results for Quarter and Nine Months ended December 31, 2023 along with limited review report for the quarter and nine months ended December 31, 2023. JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Board Meeting Outcome for Outcome Of Board Meeting Held On February 02, 2024 Along With Unaudited Financial Results For The Quarter And Nine Months Ended December 31, 2023
Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved the Unaudited Financial Results for the quarter and nine months ended December 31, 2023. In this regard, kindly find enclosed the Unaudited Financial Results along with its Limited Review Report by the Statutory Auditors of the Company for the quarter and nine months ended December 31, 2023. The Board Meeting commenced at 04:15 p.m. and concluded at 05:05 p.m. JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Board Meeting Intimation for Declaration Of Unaudited Financial Results Of The Company For The Quarter And Nine Months Ended December 31, 2023.
JAGSONPAL PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/02/2024 ,inter alia, to consider and approve Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2023. JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
In compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulation, 2018 we are enclosing herewith a copy of the certificate received from M/S MCS Share Transfer Agent Limited, the Registrar and Share Transfer agent of the Company, for the quarter ended December 31, 2023. JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Pursuant to SEBI LODR Regulations, 2015 as amended, we are pleased to inform you that the Nomination and Reumneration Committee has issued and alloted 50,000 Equity Shares of Rs. 5/- Each under JPL ESOP 2022, to the eligible employees of the Company upon the excercise of vested options. These shares shall rank pari passu with the existing equity shares of the Company in all respects. JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Closure of Trading Window
In terms of SEBI (PIT) Regulations, 2015 and Company'' s Code of Conduct to regulate and report trading by designated persons & Immediate relatives by Designated Persons, the Trading Window for dealing in securities of Jagsonpal Pharmaceuticals Limited ("the Company") shall remain closed for deisgnated persons from January 01, 2024 till end of 48 hours after the declaration of Unaudited Financial Results for the quarter and nine months ended December 31, 2023.